Merrimack Ends the Phase II Hermione Trial of MM-302

December 28, 2016

Cambridge, Massachusetts-based Merrimack Pharmaceuticals halted its Phase II study of MM-302 for the treatment of HER2-positive metastatic breast cancer in patients that have previously been treated with trastuzumab, pertuzumab and ado-trastuzumab emtansine.

The decision was based on findings that both the treatment and control arms were found to have shorter than expected median progression-free survival. Merrimack plans to provide more details in January 2017.

View today's stories